Composition for preventing hair loss or promoting hair growth

ABSTRACT

The present invention relates to a composition for preventing the hair loss or promoting the hair growth, and according to the present invention, Wnt protein-derived peptides, polydeoxyribonucleotides or mixtures thereof increase the secretion of β-catenin, and increase the growth of keratinocytes, fibroblasts and dermal papilla cells which are hair constituent cells, by the cell activation and activation of signal transduction pathway for promoting the hair growth signaling system and to prevent the hair loss and promote the hair growth and therefore, Wnt protein-derived peptides, polydeoxyribonucleotides or mixtures thereof having the above effect can be used as a cosmetic composition, a pharmaceutical composition or a health food composition for preventing the hair loss or promoting the hair growth.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to and the benefit of Korean PatentApplication No. 10-2019-0039708 filed in the Korean IntellectualProperty Office on 04, 04, 2019, the entire contents of which areincorporated herein by reference.

BACKGROUND OF THE DISCLOSURE 1. Field of the Disclosure

The present invention relates to a composition for preventing hair lossor promoting hair growth comprising a novel Wnt protein-derived peptide,polydeoxyribonucleotide or a mixture thereof as an active ingredient.

2. Description of the Related Art

Hair is a solid cone fiber composed of tightly adhered and keratinizedepithelial cells and about 100,000 to 150,000 hairs are formed in thehair follicles of the scalp, and it has been known that the number ofhair follicles is determined at birth and is not generated further afterbirth. Each hair represents a different cycle: an anagen in which hairgrows, a catagen in which its growth stops and the hair bulb shrinks,and a telogen in which the dermal papilla starts to act or develop newhair, thereby resulting in the loss of old hair and the hair grows andfalls off by repeating this cycle. This cycle is repeated over three tosix years, ranging from 3-5 years for men and 4-6 years for women.Normally, it is known that 50-70 hairs are fallen off on daily average,and hair at the anagen, catagen and telogen account for about 88%, 1%and 11% of the total hair, respectively.

Alopecia refers to a symptom in which hairs of at least 100 hairs aredropped out per day, hair at the anagen is decreased, and hairs at thecatagen and the telogen are increased. As the hair loss progresses, thehair rate of the telogen is rapidly increased and the hair rate of theanagen is decreased, accordingly. Hair loss may generally includehereditary androgenetic alopecia (baldness), alopecia areata, tineacapitis due to fungal infections, telogen alopecia, trichoti lomania,hair growth disorders and the like. The most common hair loss includesbaldness (male-pattern alopecia), female-pattern alopecia, alopeciaareata, and telogen effluvium, etc.

The causes of hair loss are various. Genetic factors and male hormone,androgen are considered important factors for baldness, and somefemale-pattern alopecia are estimated to be caused in the same route asmale-pattern alopecia, but there are differences of clinical pattern.Alopecia areata is thought to be caused by autoimmune diseases. Telogenalopecia is a temporary hair loss that occurs after severe physical andmental stress, such as endocrine diseases, nutritional deficiencies,drugs, childbirth, fever and surgery and it occurs by being fallen offdue to transition to telogen of the part of the hair which does not gothrough the growth period

Currently, there are only two FDA-approved hair loss treatment products:Finasteride and Minoxidil. Finasteride, which is male-pattern alopeciaremedy, inhibits hair loss by using a mechanism of inhibiting5α-reductase, an enzyme that converts male hormones intodihydrotestosterone (DHT), a hair loss-inducing factor, as a male hairloss treatment agent. Minoxidil inhibits hair loss by increasing bloodflow to the scalp. However, these therapies constantly are reported tohave some side effects, and also, their treatment effect is temporaryand limited. Hair loss is caused by a combination of factors, not anyone cause and the resolution of some causes cannot completely cure it.

Accordingly, various researches on hair loss have been conducted inwestern medicine and oriental medicine, and various treatment methodshave been tried. Researches on natural products, steroids, autoimmunesuppression, etc. are being conducted, and treatments using lasertherapy, autologous platelet-rich plasma application, derma roller orstem cells, etc. have been performed. However, these treatments also donot approach complexly to solve the causes of various hair loss, andscientifically untested medical procedures have a disadvantage in thatthey are ineffective compared to price. Therefore, there is an urgentneed to develop new medication for hair loss which is scientificallyproven and more economical in terms of cost.

SUMMARY OF THE DISCLOSURE

An object of the present invention is to provide a peptide forpreventing the hair loss or promoting the hair growth.

Another object of the present invention is to provide a cosmeticcomposition for preventing the hair loss or promoting the hair growth.

The third object of the present invention is to provide a pharmaceuticalcomposition for preventing the hair loss or promoting the hair growth.

The fourth object of the present invention to provide a health foodcomposition for preventing the hair loss or promoting the hair growth.

In order to achieve the above object, the present invention provides apeptide comprising at least anyone amino acid sequence selected from thegroup consisting of SEQ ID NO: 1 and SEQ ID NO: 2.

Also, the present invention also provides a cosmetic composition forpreventing hair loss or promoting hair growth comprising a peptidecomprising at least anyone amino acid sequence selected from the groupconsisting of SEQ ID NO: 1 and SEQ ID NO: 2, polydeoxyribonucleotide ora mixture thereof, as an active ingredient.

In addition, the present invention also provides a pharmaceuticalcomposition for preventing hair loss or promoting hair growth comprisinga peptide comprising at least anyone amino acid sequence selected fromthe group consisting of SEQ ID NO: 1 and SEQ ID NO: 2,polydeoxyribonucleotide or a mixture thereof, as an active ingredient.

Furthermore, the present invention provides a health food compositionfor preventing hair loss or promoting hair growth comprising a peptidecomprising at least anyone amino acid sequence selected from the groupconsisting of SEQ ID NO: 1 and SEQ ID NO: 2, polydeoxyribonucleotide ora mixture thereof, as an active ingredient.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the results of high performance liquid chromatographyanalysis of novel peptide-1 (Wnt-1, SEQ ID NO: 1) and peptide-2 (Wnt-2,SEQ ID NO: 2), which are derived from Wnt protein.

FIG. 2 shows the effect of promoting cell growth bypolydeoxyribonucleotide (PDRN) using dermal papilla cells, andmicroscopic images thereof.

FIG. 3 shows the effect of promoting cell growth by Wnt-1 or Wnt-2 using(A) keratinocytes, (B) fibroblasts and (C) dermal papilla cells, andmicroscopic images thereof.

FIG. 4 shows the effect of promoting cell growth by (A) Wnt-1+PDRN or(B) Wnt-2+PDRN using keratinocytes, and microscopic images thereof.

FIG. 5 shows the effect of promoting cell growth by Wnt-1+Wnt-2+PDRNusing dermal papilla cells, and microscopic images thereof.

FIG. 6 shows the effect of increasing the activity of β-catenin by (A)PDRN, (B) Wnt-1, Wnt-2, Wnt-1 and Wnt-2, (C) Wnt-1 and Wnt-2 usingdermal papilla cells.

FIG. 7 shows the effect of increasing the activity of c-myc by (A) PDRN,B) Wnt-1, Wnt-2, Wnt-1+Wnt-2, Wnt-1+PDRN, Wnt-2+PDRN, Wnt-1+Wnt-2+PDRNusing dermal papilla cells.

FIG. 8 shows the hair growth effect by Wnt-1+Wnt-2+PDNR using thehair-removed C57BL/6 mice.

DETAILED DESCRIPTION OF THE EMBODIMENTS

The inventors of the present invention confirmed that novel Wntproteins-derived peptides (Wnt-1 or/and Wnt-2), polydeoxyribonucleotidesor mixtures thereof activate the Wnt signaling system to increase thesecretion and activity of β-catenin and to promote the growth ofkeratinocytes, fibroblasts and dermal papilla cells, which are importantfor hair root generation, and to induce hair differentiation at theanagen, and completed the present invention.

Accordingly, the present invention provides a peptide comprising atleast anyone amino acid sequence selected from the group consisting ofSEQ ID NO: 1 and SEQ ID NO: 2.

The peptide may be acetylated at the N-terminus of the amino acidsequence.

The peptide may be a peptide derived from Wnt protein. The Wntprotein-derived peptide is a peptide that performs a function similar tothat of a natural Wnt protein and binds to a receptor to perform afunction such as that of a growth factor.

The peptide may prevent the hair loss and promote the hair growth.

The present invention also provides a cosmetic composition forpreventing hair loss or promoting hair growth comprising a peptidecomprising at least anyone amino acid sequence selected from the groupconsisting of SEQ ID NO: 1 and SEQ ID NO: 2, polydeoxyribonucleotide ora mixture thereof, as an active ingredient.

The peptide may be acetylated at the N-terminus of the amino acidsequence.

The peptide may be a peptide derived from Wnt protein. The Wntprotein-derived peptide is a peptide that performs a function similar tothat of a natural Wnt protein and binds to a receptor to perform afunction such as that of a growth factor.

The polydeoxyribonucleotide is separated from the testis of fish and thefish may be selected from the group consisting of salmon, trout,herring, pollock and cod, but it is not limited thereto.

The polydeoxyribonucleotide may have a number average molecular weightof 350 to 2000 kDa.

In addition, the composition increases the secretion of β-catenin topromote the growth of keratinocytes, fibroblasts and dermal papillacells, and increases the expression of c-myc, thereby preventing thehair loss and promoting the hair growth.

The composition may be formulated in a formulation selected from thegroup consisting of hair tonic, hair conditioner, hair essence, hairlotion, hair nutrition lotion, hair shampoo, hair rinse, hair treatment,hair cream, hair nourishing cream, hair moisturizer cream, hair massagecream, hair wax, hair aerosol, hair pack, hair nutrition pack, hairsoap, hair cleansing foam, hair oil, hair drying agent, hairpreservative, hair dye, hair wave agent, hair bleach, hair gel, hairglaze, hair dressinger, hair lacquer, hair moisturizer, hair mousse andhair spray, but it is not limited thereto.

When the composition of the present invention is a cosmetic composition,the cosmetic composition may include, in addition to the activeingredient, conventional auxiliaries such as stabilizers, solubilizers,vitamins, pigments and flavors, and carriers. In addition, the cosmeticcomposition may further include a skin absorption enhancer to enhancethe effect.

When the composition of the present invention is a cosmetic composition,the formulation of the cosmetic composition may be prepared in anyformulation commonly prepared in the art, for example, the cosmeticcomposition may be face lotion, emulsion, skin lotion, toner, lotion,essence, sunscreen, cream, makeup base, foundation, powder, pack, gel,ointment, patch, stick, shampoo, rinse, spray, makeup remover andcleanser, etc., but it is not limited thereto.

When the formulation is paste, cream or gel, it may use animal oil,vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative,polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide andthe like, as the carrier component.

When the formulation is powder or spray, it may use lactose, talc,silica, aluminum hydroxide, calcium silicate or polyamide powder, as thecarrier component, and in particular, the spray may additionally includea propellant such as chlorofluorohydrocarbon, propane/butane or dimethylether.

When the formulation is solution or emulsion, solvent, solubilizer oremulsifying agent are used as the carrier component, for examples water,ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol,benzyl benzoate, propylene glycol, 1,3-butylglycol oil, glycerolaliphatic ester, polyethylene glycol or fatty acid esters of sorbitan.

When the formulation is suspension, it may use liquid diluents such aswater, ethanol or propylene glycol, suspending agents such asethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters, andpolyoxyethylene sorbitan esters, microcrystalline cellulose, aluminummetahydroxide, bentonite, agar or tragacanth, as the carrier component.

The present invention also provides a pharmaceutical composition forpreventing hair loss or promoting hair growth comprising a peptidecomprising at least anyone amino acid sequence selected from the groupconsisting of SEQ ID NO: 1 and SEQ ID NO: 2, polydeoxyribonucleotide ora mixture thereof, as an active ingredient.

The peptide may be acetylated at the N-terminus of the amino acidsequence.

When the composition according to the present invention is apharmaceutical composition, for administration, it may include apharmaceutically acceptable carrier, excipient or diluent in addition tothe active ingredient described above. The carrier, excipient anddiluent may include lactose, dextrose, sucrose, sorbitol, mannitol,xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin,calcium phosphate, calcium silicate, cellulose, methyl cellulose,microcrystalline cellulose, polyvinylpyrrolidone, water,methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearateand mineral oil.

The pharmaceutical compositions according to the present invention maybe formulated in the form of oral formulations such as powders,granules, tablets, capsules, suspensions, emulsions, syrups or aerosols,external preparations, suppositories or sterile injectable solutionsaccording to respective conventional methods. In detail, whenformulated, it may be prepared by using diluents or excipients such asfillers, bulking agents, binders, wetting agents, disintegrating agents,and surfactants which are commonly used. Solid preparations for oraladministration include tablets, pills, powders, granules, capsules andthe like, but they are not limited thereto. Such solid preparations maybe prepared by mixing at least one excipient such as starch, calciumcarbonate, sucrose, lactose, gelatin, etc. in addition to the activeingredient. In addition to simple excipients, lubricants such asmagnesium stearate, talc may also be used. It may be prepared by addingvarious excipients such as humectants, sweeteners, fragrances,preservatives and the like in addition to liquids or liquid paraffin fororal use. Formulations for parenteral administration include sterileaqueous solutions, non-aqueous solvents, suspensions, emulsions, freezedrying agents. As the non-aqueous solvents and suspensions, propyleneglycol, polyethylene glycol, vegetable oils such as olive oil,injectable esters such as ethyl oleate, and the like may be used. As thebase of the suppository, witepsol, macrogol, tween 61, cacao butter,laurinum, glycerogelatin and the like may be used.

Suitable dosages of the pharmaceutical compositions of the presentinvention vary according to the condition and weight of the patient, theseverity of the disease, the form of the drug, and the time, but can beappropriately selected by those skilled in the art, and therefore thedaily dosage of the composition is preferably 0.001 mg/kg to 50 mg/kgand it can be administered once or divided into several times as needed.

The present invention provides a health food composition for preventinghair loss or promoting hair growth comprising a peptide comprising atleast anyone amino acid sequence selected from the group consisting ofSEQ ID NO: 1 and SEQ ID NO: 2, polydeoxyribonucleotide or a mixturethereof, as an active ingredient.

The peptide may be acetylated at the N-terminus of the amino acidsequence.

When the composition according to the present invention is a health foodcomposition, it may include various nutrients, vitamins, minerals(electrolytes), flavors such as synthetic flavors and natural flavors,etc., colorants and fillers (cheese, chocolate, etc.), pectic acid andits salts, alginic acid and its salts, organic acids, protective colloidthickeners, pH adjusting agents, stabilizers, preservatives, glycerin,alcohols, carbonating agents used in carbonated drinks, and the like.Besides, it may contain flesh for the preparation of natural fruitjuices, synthetic fruit juices and vegetable drinks. These componentsmay be used independently or in combination. In addition, the healthfunctional food composition may be in the form of any one of meat,sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen,gum, ice cream, soup, beverage, tea, functional water, drink, alcoholand vitamin complex.

In addition, the health functional food composition may further includea food additive and it suitability as a food additive is determined bythe standards for the applicable item in accordance with GeneralRegulations and General Test Methods of Korean Food Additives Codexapproved by the Ministry of Food and Drug Safety, unless otherwiseprovided.

Examples of the items published in the above-mentioned Korean FoodAdditives Codex include chemical synthetics such as ketones, glycine,potassium citrate, nicotinic acid, and cinnamic acid and the like,natural additives such as persimmon extract, licorice extract,crystalline cellulose, kaoliang color and guar gum and the like, mixedpreparations such as L-sodiumglutamate preparation, alkaline agents fornoodles, preservative formulation and a tar color formulation and thelike.

At this time, the content of the composition according to the presentinvention added to the food during the production of the healthfunctional food composition can be appropriately increased or decreasedas needed.

Hereinafter, examples will be described in detail to help understand thepresent invention. However, the following examples are merely toillustrate the content of the present invention is not limited to thescope of the present invention. The embodiments of the present inventionare provided to more completely explain the present invention to thoseskilled in the art.

Example 1: Preparation of Novel Peptides Derived from Wnt Protein

In order to produce a novel peptide derived from the Wnt protein of thepresent invention, the Wnt protein family was examined and the functionof each part of the Wnt protein was predicted using the BlastP program.Of these, the potential binding to receptor proteins is explored and theamino acid sequence of the predicted site was optimized to select andconstruct the peptide of the present invention.

A peptide was synthesized by Peptron. A desired peptide was synthesizedby Fmoc solid-phase method in the automatic peptide synthesizer(PeptrEX-R48) and the synthetic peptide was separated from the resin.The peptide was purely separated and analyzed by reverse-phase HPLC(Prominence LC-20AB, Shimadzu, Japan) using Shiseido capcell pak C18analytical RP column. The peptide is represented by the amino acidsequence of Table 1 below and the N-terminus of the amino acid sequenceis acetylated (FIG. 1).

TABLE 1 Amino acid sequence Wnt-1 MCCGRGYDQF Wnt-2 MCCGRGYNYH

Example 2: Analysis of Cell Growth by Polydeoxyribonucleotides

Dermal papilla cells (Promocells) were cultured in an incubator at 37°C., 5% CO₂ using DMEM medium (Dulbeco's Modified Eagle's Medium)containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.

Cells were recovered by treating the cultured cells with trypsin/EDTA,and then the number of cells was measured using a hemacytometer. Thecells were seeded in 96 well plates at 3×10³ cells/200 μL/well and thenstabilized for at least 4 hours. Thereafter, the medium was removed,diluted in DEME medium so as to be the polydeoxyribonucleotide (PDRN) of50, 100, 200 μg/mL concentration and then treated with cells andcultured for 72 hours in an incubator at 37° C., 5% CO₂.

Subsequently, the cells were recovered by treating them withtrypsin/EDTA and then the number of cells was measured using ahematocytometer. Cell growth rate was analyzed by calculatingpercentages based on the control group without the treatment with PDRN.

As a result, as shown in FIG. 2, it was confirmed that the growth rateof the dermal papilla cells increases as the PDRN treatmentconcentration increases.

Example 3: Analysis of Cell Growth by Wnt-Derived Peptides

To confirm the shape change and proliferation rate of cells,keratinocytes T0020001 (AddexBio), fibroblasts (ATCC), and dermalpapilla cells were cultured in DMEM medium containing 10% fetal bovineserum and 1% penicillin/streptomycin.

After the cells were recovered by treating the cultured cells withtrypsin/EDTA and the number of cells was measured using ahematocytometer. The cells were seeded in 96 well plates at 3×10³cells/200 μL/well and stabilized for at least 4 hours.

Thereafter, the medium was removed, diluted with DEME medium so as to bethe Wnt peptides (Wnt-1, Wnt-2) of 10, 100, 1000, and 10000 ng/mL andthen treated with cells and cultured for 72 hours in an incubator at 37°C., 5% CO₂. The cells were then observed by a microscope to analyze themorphology and growth rate of the cells.

As a result, as shown in FIG. 3, in the keratinocytes as theconcentration of the Wnt-1 peptide increased, the growth rate of thecells was increased, and the concentration of 100 ng/mL Wnt-2 peptideshowed the highest cell growth rate (FIG. 3A). In addition, fibroblastsexhibited a growth effect at a concentration of 10 ng/mL of the Wnt-1peptide and similar cell growth rates at high concentrations, whereas nochange was observed in the Wnt-2 peptide compared to the control group(FIG. 3B). Finally, in dermal papilla cells, both Wnt-1 peptide andWnt-2 peptide showed the highest cell growth rate at 100 ng/mL (FIG.3C).

Example 4: Analysis of Cell Growth by Treatment of Wnt Peptide inConjunction with PDRN

As in Example 1, the dermal papilla cells were seeded in 96 well platesat 3×10³ cells/200 μL/well and stabilized for at least 4 hours.Thereafter, the medium was removed, diluted with DEME medium so as to bepolydeoxyribonucleotide (PDRN, BR Pharm Co. Ltd.) of 25, 50, 100 μg/mLand Wnt-1 peptide+Wnt-2 peptide of 0.1 μg/mL (each 0.05 μg/mL) and thentreated with cells and cultured for 72 hours in an incubator at 37° C.,5% CO₂.

Subsequently, the cells were recovered by treating them withtrypsin/EDTA and then the number of cells was measured using ahematocytometer. Cell growth rate was analyzed by calculatingpercentages based on the control group without the treatment with PDRN.

As a result, as shown in FIG. 5, when the treatment was performed inconjunction with PDRN, the growth rate of the cells was increased, andalso, as the treatment concentration of PDRN increased, the growth rateof the dermal papilla cells was increased, compared with the Wnt-1+Wnt-2alone treatment.

Example 5: Expression Analysis of β-Catenin and c-Myc

As in Example 1, the dermal papilla cells were stabilized for at least 4hours after seeding in 6 well plates at 4×10⁴ cells/well. Thereafter,the medium was removed, and the cell was treated with PDRN, Wnt-1peptide and Wnt-2 peptide at various concentrations alone or incombination and incubated for 72 hours in an incubator at 37° C., 5%CO₂.

Then, the cells were lysed by adding lysis buffer (1 M Tris-HCl, 0.5 MEDTA, 1% Triton X-100, 100 mM PMSF) to each cell, and the protein wasquantified using a BCA (Bicinconinic acid) kit. 20 μg of protein wasloaded on 10% SDS-polyacrylamide and electrophoresed at 125 V. Theprotein separated by electrophoresis was transferred to PVDF membrane(Immobilon-P transfermembrane) by electrophoresis at 50 mA for 120minutes using transfer buffer (20% methanol, 25 mM Tris-HCl, 192 mMglycine).

To prevent nonspecific binding, the membranes were blocked with 5%non-fat skim milk and then the reaction was carried out at 4° C. for 12hours with a primary antibody (β-catenin, c-myc, Santa CruzBiotechnology, Inc.) diluted to 1:1000 in TTBS solution (137 mM Tris-CI,pH 7.4; 20 mM NaCl; 0.05% Tween-20). Thereafter, the membrane was washedthree times with TTBS and reacted with a secondary antibody(HRP-conjugated anti-rabbit IgG) diluted to 1:2000 at room temperaturefor 2 hours. The membrane was then washed three times with TTBS and thenprotein expression was confirmed on the X-ray film using an ECLdiagnostic kit.

As a result, as shown in FIG. 6, when the treatment was performed incombination of Wnt-1+Wnt-2, the expression of β-catenin increasedcompared with the Wnt-1 or Wnt-2 alone treatment, and when the PDRNadditionally treated, it was confirmed that the expression of β-cateninincreased in concentration-dependent manner.

In addition, as shown in FIG. 7, the expression of c-myc increased asthe treatment concentration of PDRN increased, and when Wnt was treatedin conjunction with PDRN, it was confirmed that the expression of c-mycincreased.

Example 6: Analysis of the Effect of Promoting Hair Growth on Treatmentof Wnt Peptide in Conjunction with PDRN in C57BL/6 Mice

In order to analyze the effect of promoting hair growth by treatment ofWnt peptide (Wnt-1+Wnt-2) in conjunction with PDRN, in vivo hair growthexperiments were performed using C57BL/6 mice, which are most used forhair growth testing.

Seven-week-old female C57BL/6 mice (Orient Bio Co., Ltd.) with similarweight to each other were subjected to experiments at the age of 8 weeksafter acclimatization for 1 week at 25° C. and 50% humidity. The mousewas placed in a desiccator containing ether, anesthetized for 1 minute,and the hair on the back of the mouse was removed with a hair removalcream. Wnt peptide (Wnt-1+Wnt-2, 5 μg/mL or 15 μg/mL) and PDRN (2.5mg/mL or 7.5 mg/mL) were applied transdermally to the back area from theday of hair removal and 200 μL of the sample was applied once a day.After application for 15 days, photographs were taken to confirm thedegree of hair growth by checking the color change of the applicationsite. Minoxidil of 3% was used as a positive control and phosphatebuffer was used as a negative control.

As a result, as shown in FIG. 8, the group having the treatment of Wntpeptide (Wnt-1+Wnt-2) in conjunction with PDRN dramatically increasedthe hair growth compared with the negative control group and exhibitedthe hair growth effect similar to the positive control level.

According to the present invention, Wnt protein-derived peptides,polydeoxyribonucleotides or mixtures thereof increase the secretion ofβ-catenin, and increase the growth of keratinocytes, fibroblasts anddermal papilla cells which are hair constituent cells, by the cellactivation and activation of signal transduction pathway for promotingthe hair growth signaling system and to prevent the hair loss andpromote the hair growth and therefore, Wnt protein-derived peptides,polydeoxyribonucleotides or mixtures thereof having the above effect canbe used as a cosmetic composition, a pharmaceutical composition or ahealth food composition for preventing the hair loss or promoting thehair growth.

As described above in detail specific parts of the present invention, itis apparent to those skilled in the art that these specific descriptionsare merely preferred embodiments, and the scope of the present inventionis not limited thereto. Accordingly, the substantial scope of thepresent invention will be defined by the appended claims and equivalentsthereof.

The scope of the present invention is represented by the followingclaims, and it should be construed that all changes or modificationsderived from the meaning and scope of the claims and their equivalentsare included in the scope of the present invention.

1. A peptide comprising at least anyone amino acid sequence selectedfrom the group consisting of SEQ ID NO: 1 and SEQ ID NO:
 2. 2. Thepeptide of claim 1, wherein the peptide is acetylated at N-terminus ofthe amino acid sequence.
 3. The peptide of claim 1, wherein the peptideis a peptide derived from Wnt protein.
 4. The peptide of claim 1,wherein the peptide is a peptide for preventing hair loss or promotinghair growth.
 5. A method of preventing hair loss or promoting hairgrowth in a subject, comprising: providing a cosmetic compositioncomprising a peptide comprising at least anyone amino acid sequenceselected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2,polydeoxyribonucleotide or a mixture thereof, as an active ingredient;and administering the cosmetic composition to the subject, wherein thehair loss is prevented or the hair growth is promoted.
 6. The method ofclaim 5, wherein the peptide is acetylated at N-terminus of the aminoacid sequence.
 7. The method of claim 5, wherein the peptide is apeptide derived from Wnt protein.
 8. The method of claim 5, wherein thepolydeoxyribonucleotide is separated from fish testis.
 9. The method ofclaim 8, wherein the fish is selected from the group consisting ofsalmon, trout, herring, pollock and cod.
 10. The method of claim 5,wherein the polydeoxyribonucleotide has a number average molecularweight of 350 to 2000 kDa.
 11. The method of claim 5, wherein thecomposition promotes growth of keratinocytes, fibroblasts and dermalpapilla cells by increasing secretion of β-catenin.
 12. The method ofclaim 5, wherein the composition increases c-myc expression.
 13. Themethod of claim 5, wherein the composition is formulated in aformulation selected from the group consisting of hair tonic, hairconditioner, hair essence, hair lotion, hair nutrition lotion, hairshampoo, hair rinse, hair treatment, hair cream, hair nourishing cream,hair moisturizer cream, hair massage cream, hair wax, hair aerosol, hairpack, hair nutrition pack, hair soap, hair cleansing foam, hair oil,hair drying agent, hair preservative, hair dye, hair wave agent, hairbleach, hair gel, hair glaze, hair dressinger, hair lacquer, hairmoisturizer, hair mousse and hair spray.
 14. A method of preventing hairloss or promoting hair growth in a subject, comprising: providing apharmaceutical composition comprising a peptide comprising at leastanyone amino acid sequence selected from the group consisting of SEQ IDNO: 1 and SEQ ID NO: 2, polydeoxyribonucleotide or a mixture thereof, asan active ingredient; and administering the pharmaceutical compositionto the subject, wherein the hair loss is prevented or the hair growth ispromoted.
 15. The method of claim 14, wherein the peptide is acetylatedat N-terminus of the amino acid sequence. 16-17. (canceled)